MA40814A1 - Compositions pharmaceutiques pour thérapie combinée - Google Patents

Compositions pharmaceutiques pour thérapie combinée

Info

Publication number
MA40814A1
MA40814A1 MA40814A MA40814A MA40814A1 MA 40814 A1 MA40814 A1 MA 40814A1 MA 40814 A MA40814 A MA 40814A MA 40814 A MA40814 A MA 40814A MA 40814 A1 MA40814 A1 MA 40814A1
Authority
MA
Morocco
Prior art keywords
agonist
ppar
pharmaceutical compositions
combination therapy
combination
Prior art date
Application number
MA40814A
Other languages
English (en)
French (fr)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA40814A1 publication Critical patent/MA40814A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA40814A 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée MA40814A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
PCT/US2016/016694 WO2016127019A2 (en) 2015-02-06 2016-02-05 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
MA40814A1 true MA40814A1 (fr) 2019-08-30

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40814A MA40814A1 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Country Status (30)

Country Link
US (5) US11311557B2 (enExample)
EP (2) EP3253382B1 (enExample)
JP (2) JP7306791B2 (enExample)
KR (1) KR20170115071A (enExample)
CN (1) CN107405325B (enExample)
AR (1) AR103624A1 (enExample)
AU (2) AU2016215179B2 (enExample)
BR (1) BR112017016766B1 (enExample)
CA (1) CA2976056C (enExample)
CL (3) CL2017001983A1 (enExample)
CO (1) CO2017007959A2 (enExample)
CR (1) CR20170356A (enExample)
DK (1) DK3253382T3 (enExample)
EA (1) EA036404B1 (enExample)
EC (1) ECSP17057848A (enExample)
ES (1) ES2905872T3 (enExample)
GT (1) GT201700174A (enExample)
IL (2) IL253719B (enExample)
MA (1) MA40814A1 (enExample)
MX (1) MX388508B (enExample)
NI (1) NI201700100A (enExample)
PE (1) PE20180027A1 (enExample)
PH (1) PH12017501384A1 (enExample)
SG (1) SG11201706347SA (enExample)
SV (1) SV2017005512A (enExample)
TN (1) TN2017000344A1 (enExample)
TW (1) TW201628625A (enExample)
UA (1) UA125744C2 (enExample)
WO (1) WO2016127019A2 (enExample)
ZA (1) ZA201706007B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
EA036757B1 (ru) * 2015-04-07 2020-12-17 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
RS66930B1 (sr) * 2016-03-31 2025-07-31 Genfit Elafibranor za upotrebu u lečenju primarnog bilijarnog holangitisa
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
KR20190117632A (ko) * 2017-02-21 2019-10-16 장피트 Ppar 효현제와 fxr 효현제의 병용
US20190076500A1 (en) * 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
EP3952855A1 (en) * 2019-04-10 2022-02-16 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
CA3142358A1 (en) * 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
CA3139291A1 (en) * 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
US20220370467A1 (en) * 2019-09-20 2022-11-24 Reneo Pharmaceuticals, Inc. Using of a ppar-delta agonist in the treatment of kidney disease
CN114929214A (zh) * 2019-11-22 2022-08-19 阿沃林特有限公司 Sglt2抑制剂治疗原发性胆汁性胆管炎的用途
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
EP4583874A1 (en) * 2022-12-21 2025-07-16 Charles University, Faculty Of Pharmacy In Hradec Kralove Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (enExample) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (enExample) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (enExample) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ES2156120T3 (es) 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP0001938A3 (en) 1997-01-24 2001-09-28 Univ California Use of fxr, pparalpha and lxralpha activators for producing pharmaceutical compositions useful for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation
WO1999011263A1 (en) * 1997-08-29 1999-03-11 Pfizer Products Inc. Combination therapy comprising amlodipine and a statin compound
US6054453A (en) 1997-10-27 2000-04-25 Redd's Research Foundation Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
JP2002532539A (ja) 1998-12-18 2002-10-02 アボット・ラボラトリーズ 脂質調節剤を含む新規な製剤
AU2389100A (en) 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
PL357674A1 (pl) 2000-04-19 2004-07-26 Thomas Julius Borody Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
WO2002024632A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
DE60205891T2 (de) 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. Steroide als agonisten für fxr
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
EP3175855B1 (en) 2004-03-12 2020-07-15 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
US20090312297A1 (en) * 2006-03-22 2009-12-17 President And Fellows Of Harvard College Methods for treating hypercholesterolemia and atherosclerosis
AR061101A1 (es) 2006-05-24 2008-08-06 Lilly Co Eli Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende
CN101448791B (zh) 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
PL2040713T3 (pl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
US20090318496A1 (en) 2006-08-04 2009-12-24 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8772342B2 (en) * 2009-11-26 2014-07-08 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
PT3336097T (pt) 2012-06-19 2020-10-29 Intercept Pharmaceuticals Inc Preparação da forma não cristalina de ácido obeticólico
CN108250264A (zh) 2012-10-26 2018-07-06 英特塞普特医药品公司 制备胆汁酸衍生物的方法
EA030152B1 (ru) * 2013-05-14 2018-06-29 Интерсепт Фармасьютикалз, Инк 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Also Published As

Publication number Publication date
AR103624A1 (es) 2017-05-24
US12337003B2 (en) 2025-06-24
US20220280533A1 (en) 2022-09-08
CN107405325A (zh) 2017-11-28
CN107405325B (zh) 2021-11-12
MX388508B (es) 2025-03-20
EA036404B1 (ru) 2020-11-06
IL290823A (en) 2022-04-01
UA125744C2 (uk) 2022-06-01
US20220280534A1 (en) 2022-09-08
ZA201706007B (en) 2019-01-30
EP3253382A2 (en) 2017-12-13
BR112017016766A2 (pt) 2018-04-10
MX2017010131A (es) 2017-11-01
US20250367217A1 (en) 2025-12-04
CO2017007959A2 (es) 2017-10-31
JP7306791B2 (ja) 2023-07-11
CR20170356A (es) 2018-02-28
ES2905872T3 (es) 2022-04-12
AU2016215179B2 (en) 2021-02-25
IL253719B (en) 2022-04-01
NI201700100A (es) 2018-09-06
EP3253382B1 (en) 2021-11-17
WO2016127019A3 (en) 2016-11-03
CA2976056A1 (en) 2016-08-11
TN2017000344A1 (en) 2019-01-16
EA201791770A1 (ru) 2017-12-29
US20180008616A1 (en) 2018-01-11
CA2976056C (en) 2024-02-06
BR112017016766B1 (pt) 2023-11-07
EP4035665A1 (en) 2022-08-03
JP2018504438A (ja) 2018-02-15
TW201628625A (zh) 2016-08-16
KR20170115071A (ko) 2017-10-16
SG11201706347SA (en) 2017-09-28
EP3253382A4 (en) 2018-10-31
CL2017001983A1 (es) 2018-04-20
US20250367216A1 (en) 2025-12-04
GT201700174A (es) 2018-11-13
WO2016127019A2 (en) 2016-08-11
AU2021201015A1 (en) 2021-03-11
AU2016215179A1 (en) 2017-08-24
SV2017005512A (es) 2018-06-12
CL2018001006A1 (es) 2018-06-15
DK3253382T3 (da) 2022-02-14
HK1246191A1 (zh) 2018-09-07
ECSP17057848A (es) 2017-10-31
PE20180027A1 (es) 2018-01-09
JP2022000483A (ja) 2022-01-04
IL253719A0 (en) 2017-09-28
PH12017501384A1 (en) 2018-01-08
CL2018003604A1 (es) 2019-02-22
US11311557B2 (en) 2022-04-26

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA46990B1 (fr) Compositions glp-1 et ses utilisations
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40290A1 (fr) Agents immunorégulateurs
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
EP4008718A4 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA53010B1 (fr) Formulations d'un inhibiteur de axl/mer
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39319A1 (fr) Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP4023232A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER WITH ANTI-CANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS
EP3741366A4 (en) COMPOSITION WITH DUNNION AS AN ACTIVE INGREDIENT TO PREVENT OR RELIEVE HAIR LOSS
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
FR3040303B1 (fr) Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca